Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain

Simon Haroutiunian, Gila Rosen, Rivka Shouval, Elyad Davidson

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Cannabinoids have been used for pain relief for centuries and recent studies have investigated their analgesic and anti-inflammatory mechanisms, as well as clinical efficacy, in treating chronic pain. We report an open-label study addressed to evaluate the effect and adverse events of orally administered -9-tetrahydrocannabinol ( -9-THC) in 13 patients with chronic nonmalignant pain (CNMP) unresponsive to conventional pharmacotherapy. The effect of the treatment was assessed on an eight-item HRQoL questionnaire. Five out of 13 patients reported adequate response to the treatment while eight patients reported inadequate or no response. Seven patients did not experience any adverse events (AEs), six patients reported AEs, two of which discontinued the treatment. We conclude that oral THC may be a valuable therapeutic option for selected patients with CNMP that are unresponsive to previous treatments, though further research is warranted to characterize those patients.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalJournal of Pain and Palliative Care Pharmacotherapy
Volume22
Issue number3
DOIs
StatePublished - Oct 15 2008
Externally publishedYes

Keywords

  • CNMP
  • Chronic nonmalignant pain
  • Fibromyalgia
  • THC
  • Tetrahydrocannabinol

Fingerprint Dive into the research topics of 'Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain'. Together they form a unique fingerprint.

  • Cite this